Novartis India announced the launch of Pluvicto(lutetium (177Lu) vipivotide tetraxetan), the country’s first regulatory authority-approved radioligand therapy for eligible patients with Prostate-Specific Membrane Antigen (PSMA)-positive prostate cancer.
Designed to precisely target prostate cancer cells while minimizing exposure to healthy tissues, Pluvicto introduces a new treatment approach for metastatic prostate cancer, a disease that continues to place a significant physical and emotional burden on patients and families across India.
Judith Love, Region Head Asia Pacific Middle East Africa, Novartis, said, “The introduction of Pluvicto marks a meaningful step forward- bringing globally approved innovation closer to patients who need more targeted treatment options. What makes this launch especially impactful is not just the science but the opportunity to expand access through India’s growing nuclear medicine infrastructure. We remain committed to enabling access to next-generation treatments, and I’m excited about the difference Pluvicto can make for patients in India.”
Amitabh Dube, Country President and Managing Director, Novartis India, said, “In India, a large proportion of prostate cancer patients continue to be diagnosed only after the disease has progressed to a metastatic stage, limiting treatment options and impacting quality of life. With the launch of Pluvicto, we are bringing a globally recognized radioligand therapy platform to India at a time when the need for precision oncology solutions is increasing rapidly. Beyond the therapy itself, our focus is on building long-term partnerships with hospitals and healthcare stakeholders to help strengthen access pathways, multidisciplinary collaboration, and readiness for the future of nuclear medicine in India.”
Pluvicto will be made available through select hospitals and nuclear medicine centres across India as part of Novartis’ partnership-led approach for bringing radioligand therapies to India. The company is also working with healthcare stakeholders to strengthen awareness and infrastructure preparedness for precision oncology care.
